Lexeo Therapeutics
About
Technology stack
detected 2026-07-09No comments yet. Be the first to share your take.
What does Lexeo Therapeutics do?
Lexeo Therapeutics is a New York City-based, clinical-stage genetic medicine company focused on developing AAV-mediated treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease. The company leverages pioneering science and a stepwise development approach to advance its pipeline of therapeutic candidates, aiming to address significant unmet medical needs.
How much funding has Lexeo Therapeutics raised?
Lexeo Therapeutics has raised a total of $495M in funding. The most recent round on record is Public Offering.
Where is Lexeo Therapeutics headquartered?
Lexeo Therapeutics is headquartered in New York City, United States.
When was Lexeo Therapeutics founded?
Lexeo Therapeutics was founded in 2020.
What industry does Lexeo Therapeutics operate in?
Lexeo Therapeutics operates in Biotech, MedTech, HealthTech, Genomics, Drug Discovery, Clinical Trials.
How many employees does Lexeo Therapeutics have?
Lexeo Therapeutics has approximately 91 people on record.
What is Lexeo Therapeutics's revenue?
StartupHub estimates Lexeo Therapeutics's annual revenue at $11.0M (range $5.8M to $42.6M, 64% confidence), based on comparable companies in the sector.
What is Lexeo Therapeutics's valuation?
StartupHub estimates Lexeo Therapeutics's effective valuation at $2.1B (range $1.2B to $3.0B, 20% confidence), based on comparable companies in the sector.